| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2024 ( Subtotal = $0 ) |
| | 2024 | 2023 | SERPLUS TECHNOLOGY, LLC | 111 INDUSTRIAL WAY | BELMONT | CA | 94002-8206 | SAN MATEO | USA | R43IP001227 | PA-21-259, SBIR, Phase I, Serpin B1. A host-directed therapy to prevent and treat severe pulmonary influenza | 03 | 1 | CDC | 8/20/2024 | $0 |
| | 2024 | 2023 | SERPLUS TECHNOLOGY, LLC | 111 INDUSTRIAL WAY | BELMONT | CA | 94002-8206 | SAN MATEO | USA | R43IP001227 | PA-21-259, SBIR, Phase I, Serpin B1. A host-directed therapy to prevent and treat severe pulmonary influenza | 01 | 1 | CDC | 2/15/2024 | $0 |
| | 2024 | 2023 | SERPLUS TECHNOLOGY, LLC | 111 INDUSTRIAL WAY | BELMONT | CA | 94002-8206 | SAN MATEO | USA | R43IP001227 | PA-21-259, SBIR, Phase I, Serpin B1. A host-directed therapy to prevent and treat severe pulmonary influenza | 02 | 1 | CDC | 5/22/2024 | $0 |
| | 2024 | 2021 | SERPLUS TECHNOLOGY, LLC | 111 INDUSTRIAL WAY STE 9 | BELMONT | CA | 94002-8206 | SAN MATEO | USA | R41DK127818 | Enhanced pancreatic islet cell engraftment by treatment with serpin B1 | 000 | 1 | NIH | 9/13/2024 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $259,613 ) |
| | 2023 | 2023 | SERPLUS TECHNOLOGY LLC | 111 INDUSTRIAL WAY | BELMONT | CA | 94002-8206 | SAN MATEO | USA | R43IP001227 | PA-21-259, SBIR, Phase I, Serpin B1. A host-directed therapy to prevent and treat severe pulmonary influenza | 00 | 1 | CDC | 8/25/2023 | $259,613 |
| | 2023 | 2021 | SERPLUS TECHNOLOGY LLC | 111 INDUSTRIAL WAY | BELMONT | CA | 94002-8206 | SAN MATEO | USA | R41DK127818 | Enhanced pancreatic islet cell engraftment by treatment with serpin B1 | 000 | 1 | NIH | 7/14/2023 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = $244,285 ) |
| | 2021 | 2021 | SERPLUS TECHNOLOGY, LLC | 111 INDUSTRIAL WAY STE 9 | BELMONT | CA | 94002-8206 | SAN MATEO | USA | R41DK127818 | Enhanced pancreatic islet cell engraftment by treatment with serpin B1 | 000 | 1 | NIH | 9/23/2021 | $246,281 |
| | 2021 | 2018 | SERPLUS TECHNOLOGY, LLC | 111 INDUSTRIAL WAY STE 9 | BELMONT | CA | 94002-8206 | SAN MATEO | USA | R41DK115326 | Regulation of Autoimmune Type 1 Diabetes by Serpins B1 and A1 (Alpha 1-Antitrypsin) | 000 | 1 | NIH | 3/10/2021 | -$1,996 |
|
| Issue Date FY: 2020 ( Subtotal = -$1,689 ) |
| | 2020 | 2018 | SERPLUS TECHNOLOGY, LLC | 111 INDUSTRIAL WAY STE 9 | BELMONT | CA | 94002-8206 | SAN MATEO | USA | R41AI141068 | Amelioration of rhinovirus induced asthma exacerbations by serpin B1 | 000 | 1 | NIH | 11/4/2019 | -$1,689 |
|
| Issue Date FY: 2018 ( Subtotal = $441,768 ) |
| | 2018 | 2018 | SERPLUS TECHNOLOGY, LLC | 111 INDUSTRIAL WAY STE 9 | BELMONT | CA | 94002-8206 | SAN MATEO | USA | R41AI141068 | Amelioration of rhinovirus induced asthma exacerbations by serpin B1 | 000 | 1 | NIH | 5/22/2018 | $223,334 |
| | 2018 | 2018 | SERPLUS TECHNOLOGY, LLC | 111 INDUSTRIAL WAY STE 9 | BELMONT | CA | 94002-8206 | SAN MATEO | USA | R41DK115326 | Regulation of Autoimmune Type 1 Diabetes by Serpins B1 and A1 (Alpha 1-Antitrypsin) | 000 | 1 | NIH | 9/17/2018 | $218,434 |
|
|
